Antiretroviral effect of a gag-RNase HI fusion gene.
We have previously shown that a molecule consisting of a fusion of a Ca(2+)-dependent nuclease (from Staphylococcus aureus) to a retroviral coat protein specifies a potent antiviral specific for that retrovirus. Genes specifying such fusion proteins can be delivered to virus-susceptible cells, providing an antiviral gene therapy aimed at limiting virus spread. We report here the results of experiments to vary the nuclease moiety of such fusion proteins. We found that one nuclease. Serratia marcescens nuclease, was extremely toxic to host cells and hence not likely to be useful for therapeutic purposes. A second nuclease, Escherichia coli RNase Hl was found to be nontoxic and highly effective against a murine leukemia virus when it was fused to the leukemia virus coat protein. The fusion protein was enzymatically active and stably expressed, without apparent toxicity to host cells. Reduction in infectious virus output was as high as 97-99%. These studies provide a model system for the development of gene therapeutic agents aimed at combating retroviral infections in vivo.
Schumann
G
G
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Cannon
K
K
Ma
W P
WP
Crouch
R J
RJ
Boeke
J D
JD
D000818:Animals; D002213:Capsid; D004926:Escherichia coli; D015750:Genes, gag; D015316:Genetic Therapy / Q000379:methods*; D015151:Immunoblotting; D009052:Leukemia Virus, Murine / Q000235:genetics*; D007942:Leukemia, Experimental / Q000628:therapy*; D011993:Recombinant Fusion Proteins; D012192:Retroviridae Infections / Q000628:therapy*; D016914:Ribonuclease H; D014412:Tumor Virus Infections / Q000628:therapy*; D014776:Virus Cultivation
D011993:Recombinant Fusion Proteins; D016914:Ribonuclease H; C078856:ribonuclease HI